MAPK3 and colonic neoplasm: Previous reports have demonstrated the ability of butyrate and propionate to inhibit colon cancer cellular proliferation (Zeng et al., 2017) or motility (Li et al., 2017) via decreasing ERK1/2 phosphorylation, which aligns with our observations.